©1996-2019. All Rights Reserved. Online Journal of Bioinformatics . You may not store these pages in
any form except for your own personal use. All other usage or distribution is
illegal under international copyright treaties. Permission to
use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher.
This article is exclusively copyrighted in its entirety to OJB publications.
This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. This journal
satisfies the refereeing requirements (DEST) for the Higher Education Research
Data Collection (Australia). Linking:To link to this page or any pages linking to this page you must link
directly to this page only here rather than put up your own page.
OJBTM
Online
Journal of Bioinformatics ©
Volume
13(2):222-231, 2012
Molecular docking of a beta-2-microglobulin
drug target
P Navya, K Hema, M Munikumar, S Swargam, A Umamaheswari.
SVIMS Bioinformatics Centre, Department of
Bioinformatics, SVIMS University, Tirupati - India,
ABSTRACT
Navya P, Hema K, Munikumar M, Swargam S, Umamaheswari A.,
Molecular docking of a beta-2-microglobulin drug target, Online J Bioinform., 13(2):222-231, 2012. Elevated
Beta-2-microglobulin (B2M) is observed in amyloidosis, peripheral arterial
disease, coronary heart disease, cancer and inflammatory disease.
B2M could be therefore be a useful drug target. The
tertiary structure of human B2M with highest resolution (1.13Å) was
pre-processed with OPLS_2005 force field using Schrödinger 2011. The four
published B2M inhibitors were subjected to 2D similarity search using Ligand.Info yielding 1589 structural analogs. The 3D structural conversion and multiple
confirmations for each compound were generated using LigPrep
with constraints of ADME evaluation and toxicity assessments. Three successive
docking modes of Glide v5.7 (HTVS, SP and XP) were implemented to propose five
potential B2M inhibitors. The five leads suggested for B2M inhibition were
based on their specific binding pattern and better binding affinity compared to
existing B2M inhibitors. Thus, the five proposed leads would be useful in
treatment of cardiovascular diseases.
Key Words
beta-2-microglobulin, disease, molecular docking, drug target
FULL-TEXT (SUBSCRIBERS OR PURCHASE TITLE $25USD)